Abstract:Background: CD44 is a potentially interesting prognostic marker and therapeutic target in non-small cell lung cancer (NSCLC). Although the expression of CD44 has been reported to correlate with poor prognosis of NSCLC in most literatures, some controversies still exist. Since the limited patient numbers within independent studies, here we performed a meta-analysis to clarify the correlations between CD44 expression and prognosis and clinicopathological features in NSCLC. Methods: Relevant literatures were identified using PubMed, EMBASE and CNKI (China National Knowledge Infrastructure) databases (up to February 2014). Data from eligible studies were extracted and included into meta-analysis using a random effects model. Studies were pooled. Summary hazard ratios (HR) and clinical parameters were calculated. Results: We performed a final analysis of 1772 patients from 23 evaluable studies for Prognostic Value and 2167 patients from 28 evaluable studies for clinicopathological features. Our study shows that the pooled hazard ratio (HR) of overexpression CD44-V6 for overall survival in NSCLC was 1.63 [95% confidence interval (CI): 1.20-2.21] by univariate analysis and 1.29 (95% CI: 0.71-2.37) by multivariate analysis.The pooled HR of overexprssion panCD44 for overall survival in NSCLC was 1.53 (95% CI: 0.58-4.04) by univariate analysis and 3.00 (95% CI: 1.53-5.87) by multivariate analysis. Overexpression of CD44-V6 is associated with tumor differentiation (poor differentiation, OR = 1.66, 95% CI: 1.12-2.45), tumor histological type [squamous cell carcinomas (SCC), OR = 2.6, 95% CI: 1.63-5.02], clinical TMN stage (TMN stage III, OR = 2.22, 95% CI: 1.443.43) and lymph node metastasis (N1-3, 3.52, 95% CI: 2.08-5.93) in patients with NSCLC. However, there was no significant association between CD44-V6 and tumor size [T category, OR = 1.42, 95% CI: 0.73-2.78]. Conclusion: Our meta-analysis showed that CD44-V6 is an efficient prognostic factor for NSCLC. Overexpression of CD44-V6 was significantly associated with tumor differentiation, tumor histological type, clinical TMN stage and lymph node metastasis. However, there was no significant association between CD44-V6 and tumor size. Large prospective studies are now needed to confirm the clinical utility of CD44 as an independent prognostic marker.

[Quantitative Studies on Expression of Peripheral Blood CD44 and CD54 in Non-Small Cell Lung Carcinoma].

[Expression and Clinical Significance of CD44v6 and Scd44v6 in Gastric Carcinoma].

The Clinical Significance of the CD44v6 Expression in Peripheral Blood Mononuclear Cell and Cancerous Tissue of Patients with Gastric Cancer

Correlation Between Abnormal Expressions of CD44 Protein and Gene and Lymph Node Metastasis for Human Lung Carcinoma

Clinical Signification on CD44 Express of Peripheral Blood Cells in Pat ients with Primary Hepatic Carcinoma

Correlative Studies Between DNA Content and Metastasis Associate Gene Expression in Patient with Non-Small Cell Lung Canner

Expression and Clinical Significance of CD44 and Nm23-H1 Proteins in Non-Small Cell Lung Cancer

Expression and its Clinical Significance of P53, CD44 and EGFR in Non-small Cell Lung Cancer

[Expression and Clinicopathological Significance of CD44V6 Expression in Non-Small Cell Lung Cancer].

Study on the correlationship between CK19mRNA and CyFRA21-1 in peripheral blood of lung cancer patients

[Multiparametric Flow Cytometry Analyzes the Expressions of Immunophenotype CD133, CD34, CD44 in Lung Cancer Naive Cells].

Prognostic value of CD 44 expression in non-small cell lung cancer : a systematic review

Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review.

Clinical significance of expression rate of cytokines in peripheral blood cells of patients with lung cancer

Relation between peripheral blood active circulating tumor cell and clinical characteristics of non-small cell lung cancer

Expression and Significance of PTEN and CD44V6 in Human Non-Small Cell Lung Cancer of 50 Patients Aged over 50 Years

Analysis of lymphocyte count in 300 lung cancer patients.]

Clinical Significance of the Expression Rates of Cytokeratin Positive Cells in Tumor Tissue and Peripheral Blood Cells from Patients with Lung Carcinoma by Flow Cytometry

Studies on the Expressions of CD44v6 and C -erbB-2 Gene Product in Human Non-Small Cell Lung Cancer

The Clinical Signiifcance of Investigating the Serum Concentrations of Scd40, Scd40l and Plasma Concentrations of CD62P in Patients with Lung Cancer

Analysis of Peripheral Blood Cell Subsets in Patients with Lung Cancer and Its Relationship with Clinic